AI assistant
Moderna, Inc. — Director's Dealing 2024
Aug 7, 2024
30610_dirs_2024-08-07_bf1146ee-3eab-411f-812d-8c9229a6756d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-08-05
Reporting Person: Rubenstein David M. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-08-05 | Stock Option (Right to Buy) | $83.75 | A | 5051 | Acquired | 2034-08-05 | Common Stock (5051) | Direct |
| 2024-08-05 | Stock Option (Right to Buy) | $83.75 | A | 4065 | Acquired | 2034-08-05 | Common Stock (4065) | Direct |
| 2024-08-05 | Restricted Stock Units | $ | A | 850 | Acquired | Common Stock (850) | Direct | |
| 2024-08-05 | Restricted Stock Units | $ | A | 677 | Acquired | Common Stock (677) | Direct |
Footnotes
F1: This option will become fully vested and exercisable on August 5, 2025.
F2: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: The shares subject to this restricted stock unit award will vest in full on August 5, 2025.
F5: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.